Puig downgraded as fragrance cycle cools; pivot needed to protect EBIT

Bottom Line Impact

Absent proactive mix diversification and inventory normalization, revenue growth could decelerate by 200-300 bps and EBITDA margins compress 50-100 bps over the next 6-12 months, risking further multiple pressure; decisive pivot to hero-led sell-out and skincare adjacency can stabilize margins and support a valuation reset.

Executive Summary

JPMorgan halved Puig's target price to €12.5 and issued the first negative call, citing a cyclical fragrance slowdown that leaves Puig highly exposed given fragrances are 72% of revenue and 86% of EBIT in FY25e. With shares down 6% on the day and EPS cuts of about 2% for 2025 and up to 12% for 2026, management must rebalance mix, recalibrate launches, and tighten trade inventories while leveraging strong H1 profitability to defend margins and sustain share gains.

Actionable Insights

Immediate Actions (Next 30-90 days)
Publish a 12-month category diversification plan to reduce fragrance mix by 300-500 bps via skincare and makeup acceleration, and commit to a reduced launch cadence focused on hero lines
Rationale: Signals control of the cycle, preserves margin, and reframes the equity story from single-category exposure to balanced growth
Role affected:CEO
Urgency level:immediate
Tighten working capital by cutting retailer weeks of supply to 8-10 weeks and reduce SKU count by 15-20%; protect EBITDA margin with a 100-150 bps SG&A flex plan
Rationale: Faster inventory turns and cost flexibility offset slower sell-in and limit margin leakage
Role affected:CFO
Urgency level:immediate
Short-term Actions (6-12 months)
Reallocate 20-30% of launch and media spend from newness to top-3 hero franchises and DTC demand capture; target +300 bps DTC mix and +2-3% ASP hold on icons
Rationale: Hero concentration drives sell-out resilience while retailers destock, sustaining pricing power and share
Role affected:CMO
Urgency level:short-term
Strategic Actions
Advance a pipeline of 1-2 bolt-on deals in derma or color cosmetics totaling €200-400m to balance category mix and add recurring skincare revenue
Rationale: Selective M&A can accelerate diversification and support a rerating once the cycle stabilizes
Role affected:Corporate Development
Urgency level:strategic

Strategic Analysis

Next 30-90 days: heightened investor scrutiny, higher perceived cost of equity, and pressure to de-risk guidance around fragrance-driven growth. Retailer destocking and reduced launch cadence will weigh on sell-in; promotional asks may rise. Puig should issue a focused update on inventory normalization, launch rationalization, and margin defense to stabilize sentiment.

Over 6-12 months, the fragrance downcycle is likely to persist through at least two to three quarters of destocking, compressing top-line growth by 200-300 bps and risking 50-100 bps of margin erosion absent action. Strategic priorities should shift to mix diversification into skincare and makeup, DTC acceleration, and selective M&A to bring fragrance exposure closer to 65-68% of revenue within 12 months.

Peers with broader beauty exposure will be more insulated as fragrances cool. Diversified luxury beauty leaders with strong skincare portfolios will lean on resilient categories, while pure-play fragrance peers face sharper volatility. Puig can still outgrow a slowing market by concentrating spend on hero franchises and gaining space from competitors curtailing launches, but must avoid over-reliance on sell-in.

Suppliers of glass, alcohol, and components will see lower order variability if launch counts are cut and core SKUs prioritized. Retail partners are likely to reduce weeks of supply and demand higher ROI marketing. Consumers may exhibit price sensitivity on non-hero SKUs, requiring tighter promotional governance and elevated storytelling on icons to preserve ASPs.

Risks & Opportunities

Primary Risks

  • Prolonged fragrance downcycle and retailer destocking lasting 3-4 quarters
  • Margin pressure from elevated promotions and mix shift away from high-EBIT icons
  • Weaker China and travel retail recovery, muting premium fragrance demand

Primary Opportunities

  • Share gains as competitors reduce launches and shelf space opens for hero franchises
  • DTC and CRM-driven sell-out growth that decouples from retailer destocking
  • Category diversification into skincare and makeup with higher repeat rates

Market Context

Fragrances led beauty growth for three years and are now normalizing as manufacturers trim launches and retailers right-size inventory. Macro headwinds including China softness and cautious US consumers, coupled with travel retail normalization, are shifting growth toward skincare and makeup. Diversified beauty leaders can offset category cyclicality, while fragrance-centric players face greater volatility. Puig retains relative strengths in brand equity and hero franchises but must align to a sell-out led model faster than peers to preserve pricing and margins.